Elevai Labs, Inc. (NASDAQ:ELAB – Get Free Report) was the recipient of a large increase in short interest in October. As of October 15th, there was short interest totalling 1,870,000 shares, an increase of 172.4% from the September 30th total of 686,400 shares. Based on an average daily volume of 16,300,000 shares, the days-to-cover ratio is currently 0.1 days. Currently, 11.3% of the company’s shares are sold short.
Elevai Labs Trading Up 9.9 %
ELAB stock traded up $0.01 during midday trading on Friday, reaching $0.10. 398,700,508 shares of the company’s stock traded hands, compared to its average volume of 42,619,560. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.05 and a quick ratio of 0.54. Elevai Labs has a fifty-two week low of $0.08 and a fifty-two week high of $4.24. The business has a 50-day moving average price of $0.20 and a two-hundred day moving average price of $0.44. The company has a market capitalization of $2.11 million and a P/E ratio of -0.32.
Elevai Labs (NASDAQ:ELAB – Get Free Report) last posted its earnings results on Wednesday, August 14th. The company reported ($0.08) earnings per share for the quarter. Elevai Labs had a negative net margin of 191.96% and a negative return on equity of 216.19%. The business had revenue of $0.61 million for the quarter.
Institutional Investors Weigh In On Elevai Labs
Elevai Labs Company Profile
Elevai Labs, Inc, a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc and changed its name to Elevai Labs, Inc in December 2021.
Further Reading
- Five stocks we like better than Elevai Labs
- What is an Earnings Surprise?
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- ETF Screener: Uses and Step-by-Step Guide
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- How to Invest in Biotech Stocks
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for Elevai Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevai Labs and related companies with MarketBeat.com's FREE daily email newsletter.